Phase-1 clinical study of tadalafil administered for selective fetal growth restriction in twin pregnancy.

Shoichi Magawa Masafumi Nii Hiroaki Tanaka Fumi H Furuhashi Shintaro Maki Michiko Kubo Kayo Tanaka Asumi Okumura Tomoaki Ikeda

Published in: The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2019)

Tadalafil has a manageable safety profile up to an MTD of 40 mg/d.

Keyphrases

lower urinary tract symptoms
benign prostatic hyperplasia
preterm birth
pregnancy outcomes
double blind
clinical trial
pregnant women